Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Juno Therapeutics (JUNO) Misses Q4 EPS by 6c
February 29, 2016 4:05 PM ESTJuno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($0.53), $0.06 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $4.79 million.
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
... More